scout
|Videos|May 15, 2020

Dr. Chaft on Immune-Related AEs in NSCLC

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Jamie E. Chaft, MD, thoracic medical oncology, Memorial Sloan Kettering Cancer Center, discusses immune-related adverse effects (irAEs) in non–small cell lung cancer (NSCLC).

Understanding when irAEs are likely to occur and how to mediate them could inform when it is safe to restart a patient on immunotherapy, explains Chaft.

Historically, irAEs were thought to be exclusively mediated by T cells, says Chaft. However, it is now understood that although some irAEs are mediated by T cells, others such as thyroiditis are likely mediated by B cells. Some irAEs may also be mediated by cytokine events.

Deciding when to restart a patient on immunotherapy depends on the severity of irAEs, explains Chaft. Additionally, the duration and impact irAEs have on patients varies.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME